Idiopathic Inflammatory Myopathies Clinical Trial
Official title:
Elastography as a Follow up Imaging Tool in Patients With Idiopathic Inflammatory Myopathies
The aim of our study was to assess the performance of compression-strain US elastography in patients with idiopathic inflammatory myopathies over time and to study these findings with clinical and functional parameters as well as biochemical and electromyographic tests.
Status | Recruiting |
Enrollment | 80 |
Est. completion date | November 1, 2020 |
Est. primary completion date | November 1, 2020 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 2 Years and older |
Eligibility | Inclusion Criteria: - to fulfill criteria of diagnosis of childhood and adult idiopathic inflammatory myopathies Exclusion Criteria: - Patients with age less than 2 years were excluded from the study due to inability to perform manual muscle testing and functional scales. - The presence of a associated illness that may result in nerve or muscle affection |
Country | Name | City | State |
---|---|---|---|
Egypt | Benha University Hospital | Banha | Qalubiya |
Lead Sponsor | Collaborator |
---|---|
Benha University |
Egypt,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Manual muscle testing | Kendall's 0 -10 point scale measures strength of each muscle group score 0 is the weakest (worst) and 10 is the strongest (best). The following muscles were tested bilaterally: the biceps brachii muscle (BB), the forearm flexors(FF), the rectus femoris muscle (RF), the tibialis anterior muscle (TA) | 6 months | |
Primary | Serum creatine kinase (CK) levels | CK measured in U/L using ELISA | 6 months | |
Primary | Serum Lactate dehydrogenase (LDH) levels | LDHmeasured in IU/L using ELISA | 6 months | |
Primary | alanine aminotransferase (ALT) | ALT measured in U/L using ELISA | 6 months | |
Primary | Aspartate aminotransferase (AST) | AST measured in U/L using ELISA | 6 months | |
Primary | motor unit potential (MUP) duration | quantitative electromyography (QEMG) in the most affected rectus femoris and biceps brachii muscles will be performed and The motor unit potentials will be reviewed offline for the needle-detected EMG signals will be analyzed by the device software for the MUP duration measured in milliseconds. | 6 months | |
Primary | motor unit peak-to-peak amplitude | quantitative electromyography (QEMG) in the most affected rectus femoris and biceps brachii muscles will be performed and The motor unit potentials will be reviewed offline for the needle-detected EMG signals will be analyzed by the device software for the peak-to-peak amplitude measured in microvolt | 6 months | |
Primary | motor unit area to amplitude ratio (AAR) | quantitative electromyography (QEMG) in the most affected rectus femoris and biceps brachii muscles will be performed and The motor unit potentials will be reviewed offline for the needle-detected EMG signals will be analyzed by the device software for the motor unit AAR . | 6 months | |
Primary | muscle echo intenisity (EI) | EI is assessed during muscle ultrasound evaluation means of computer-assisted grayscale histogram analysis of Adobe Photoshop . echo intensity was calculated based on a histogram analysis which expresses every pixel as a value between 0 (black) and 255 (white)..he following muscles were tested bilaterally: the biceps brachii muscle (BB), the forearm flexors(FF), the rectus femoris muscle (RF), the tibialis anterior muscle (TA) | 6 MONTHS | |
Primary | Childhood myositis assessment scale | used to assess the severity of muscle involvement in children with dermatomyositis. The scores for the 14 items are summated to give a total score ranging from 0 (worst) to 52 (best) | 6 months | |
Primary | MYOSITIS DISEASE ACTIVITY ASSESSMENT TOOL (MDAAT) | The MDAAT is a combined tool that includes the Myositis Disease Activity Assessment visual analog scale (VAS) (MYOACT) and the Myositis Intention to Treat Activities Index (MITAX).it Assesses 6 extramuscular organs to produce a global extramuscular score, and the muscle score, which gives a total disease activity index score. Scores range from 0-60 for the extramuscular MYOACT score and 0-70 for the total MYOACT score, and they range from 0-54 for the Extramuscular MITAX score and 0-63 for the total MITAX score. higher scores indicates worse outcome | 6 months | |
Primary | CHILDHOOD HEALTH ASSESSMENT QUESTIONNAIRE (CHAQ) | There are 30 items in the Disability Index; one item each in the Discomfort Index and Health Status Index. Score range. The range is 0-3. Higher scores reflect greater disability. | 6 months | |
Primary | HEALTH ASSESSMENT QUESTIONNAIRE (HAQ) | 20 questions grouped into eight subscales (dressing and grooming, arising, eating, walking, hygiene, reach, grip, activities). (score = 0 to 3 with higher score means worse outcome ). The highest score for any question determines the score for the subscale in question. The HAQ disability index is calculated as the sum of the scores for various subscales,divided by the number of subscales responded to, and results in a score between 0 and 3. higher score means worse outcome | 6months | |
Primary | MYOSITIS DAMAGE INDEX (MDI) | The MDI measures specific manifestations in 11 organ systems The MDI also includes a series of visual analog scales (VAS) to quantify damage severity in a given organ system. The VAS are summed together for a potential score of 0-110 with higher scores has worse prognosis | 6months | |
Primary | PHYSICIAN GLOBAL ACTIVITY assessment | visual analogue scale rating, a score of 0-10 (down to 1 decimal place) is used, higher score means worse outcome | 6 months | |
Primary | PATIENT/PARENT GLOBAL ACTIVITY assessment | visual analogue scale rating, a score of 0-10 (down to 1 decimal place) is used, higher score means worse outcome | 6 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05833711 -
Study Evaluating Efficacy and Safety of Froniglutide (PF1801) in Patients With Idiopathic Inflammatory Myopathy
|
Phase 2 | |
Recruiting |
NCT04561557 -
Safety and Efficacy of CT103A Cells for Relapsed/Refractory Antibody-associated Inflammatory Diseases of the Nervous System
|
Early Phase 1 | |
Completed |
NCT04208464 -
JAK 1/2 Inhibitor, Baricitinib, in the Treatment of Adult IIM
|
Phase 2 | |
Completed |
NCT03267277 -
Sodium Thiosulfate for Treatment of Calcinosis Associated With Juvenile and Adult Dermatomyositis
|
Phase 2/Phase 3 | |
Recruiting |
NCT06316076 -
Safety and Efficacy Study of CD19-CAR-DNT Cells in Autoimmune Diseases
|
Phase 1 | |
Not yet recruiting |
NCT06350110 -
Fourth-gen CAR T Cells Targeting BCMA/CD19 for Refractory Systemic Lupus Erythematosus (SLE)
|
Phase 1/Phase 2 | |
Recruiting |
NCT05879419 -
Recombinant Herpes Zoster Vaccine in Patients With Autoimmune Rheumatic Diseases
|
Phase 4 | |
Recruiting |
NCT04792931 -
Adult Autoimmune Myopathies (MAIA)
|
N/A | |
Not yet recruiting |
NCT06417398 -
Preliminary Clinical Study of UTAA09 Injection in the Treatment of Relapsed/Refractory Autoimmune Diseases
|
Early Phase 1 | |
Not yet recruiting |
NCT06285539 -
Drug Rediscovery for Rare Immune Mediated Inflammatory Diseases
|
Phase 2 | |
Recruiting |
NCT04664465 -
PRediction Of DIverse Glucocorticoids toxIcity OUtcomeS
|
||
Not yet recruiting |
NCT06152172 -
CARTIMMUNE: Study of Patients With Autoimmune Diseases Receiving KYV-101
|
Phase 1 | |
Recruiting |
NCT05400889 -
Clinical Characteristics and Mechanism Research of Inhibitors of Janus Kinase in the Idiopathic Inflammatory Myopathies
|
Phase 2 | |
Completed |
NCT03918356 -
Application of Electrical Impedance Myography (EIM) as a Potential Biomarker of Idiopathic Inflammatory Myopathies
|
N/A | |
Completed |
NCT00341679 -
Studies of the Natural History and Pathogenesis of Autoimmune/Connective Tissue Diseases
|
||
Recruiting |
NCT05952531 -
Characterizing Myositis With 68Ga-FAPI PET/CT
|
Early Phase 1 | |
Recruiting |
NCT05200702 -
Assessment of Safety and Acute Effects of a Knee-hip Powered Soft Exoskeleton in Patients With Neuromuscular Disorders
|
N/A | |
Completed |
NCT03092167 -
Physical Training in Patients With Idiopathic Inflammatory Myopathies
|
N/A | |
Recruiting |
NCT03092180 -
Optimizing Treatment on Idiopathic Inflammatory Myopathies
|
||
Recruiting |
NCT05199246 -
Assessment of Safety and Acute Effects of a Lower-limb Powered Dermoskeleton in Patients With Neuromuscular Disorders
|
N/A |